Share-Based Compensation and Warrants (Tables)
|
6 Months Ended |
Dec. 31, 2025 |
| Share-Based Compensation and Warrants |
|
| Schedule of the number of shares authorized, outstanding, and available for future grants under stock option |
Presented below is a summary of the number of shares authorized, outstanding, and available for future grants under the Company’s equity incentive plans as of December 31, 2025: | | | | | | | | | Number of Shares | Description | | Authorized | | Outstanding | | Available | 2015 Plan | | 14,000 | | 14,000 | | — | 2016 Plan | | 121,200 | | 121,200 | | — | 2019 Plan | | 200,000 | | 200,000 | | — | 2021 Plan | | 21,051,536 | | 14,702,929 | | 6,348,607 | Inducement Awards | | 1,500,000 | | 742,500 | | 757,500 | Total | | 22,886,736 | | 15,780,629 | (1) | 7,106,107 |
| (1) | Consists of approximately 13.2 million shares outstanding under stock option agreements and 2.6 million shares under restricted stock units. |
|
| Schedule of the stock option plans |
For the six months ended December 31, 2025, the following table summarizes the combined stock option activity under the Company’s equity incentive plans and Inducement Awards: | | | | | | | | | | Shares | | Price (1) | | Term (2) | Outstanding, beginning of period | | 13,027,994 | | $ | 4.03 | | 7.7 | Granted | | 2,221,000 | | | 9.23 | | | Exercised | | (328,134) | (3) | | 2.44 | | | Expired | | (4,700) | | | 26.84 | | | Forfeited | | (1,753,031) | | | 6.25 | | | Outstanding, end of period | | 13,163,129 | (4) | | 4.65 | | 7.0 | Vested, end of period | | 8,398,953 | (5) | | 4.34 | | 6.1 |
| (1) | Represents the weighted average exercise price. |
| (2) | Represents the weighted average remaining contractual term for the number of years until the stock options expire. |
| (3) | The total intrinsic value (the amount by which the fair market value exceeded the exercise price) of stock options exercised during the six months ended December 31, 2025, was $1.8 million. |
| (4) | As of December 31, 2025, the intrinsic value of outstanding options was approximately $2.5 million. |
| (5) | As of December 31, 2025, the intrinsic value of vested stock options was approximately $1.5 million. |
|
| Schedule of the fair value of stock options |
For the six months ended December 31, 2025, the fair value of stock options was estimated on the respective dates of grant, with the following weighted-average assumptions: | | | | | Market price of common stock on grant date | | $ | 9.23 | | Expected volatility | | | 84 | % | Risk free interest rate | | | 3.8 | % | Expected term (years) | | | 5.9 | | Dividend yield | | | 0 | % |
|
| Schedule of the combined RSU activity |
For the six months ended December 31, 2025, the following table sets forth a summary of the combined RSU activity under the Company’s 2021 Plan: | | | | | | | | Shares | | Price (1) | Unvested, beginning of period | | 1,056,500 | | $ | 4.55 | Granted | | 1,915,000 | | | 10.11 | Vested | | — | | | — | Forfeited | | (354,000) | | | 9.51 | Unvested, end of period | | 2,617,500 | | | 7.95 |
| (1) | Represents the weighted average grant price based on the closing market price on the date of each of the RSU grants. |
|
| Schedule of share-based compensation expense |
Share-based compensation expense for the three and six months ended December 31, 2025 and 2024 is included under the following captions in the unaudited condensed consolidated statements of operations and comprehensive loss (in thousands): | | | | | | | | | | | | | | | Three Months Ended | | Six Months Ended | | | December 31, | | December 31, | | | 2025 | | 2024 | | 2025 | | 2024 | Research and development | | $ | 1,578 | | $ | 721 | | $ | 2,745 | | $ | 1,433 | General and administrative | | | 1,833 | | | 724 | | | 3,197 | | | 1,412 | Total | | $ | 3,411 | | $ | 1,445 | | $ | 5,942 | | $ | 2,845 |
|
| Legacy warrants |
|
| Share-Based Compensation and Warrants |
|
| Schedule of warrant activity |
For the six months ended December 31, 2025, no Legacy Warrants were granted or exercised. The following table sets forth a summary of all Legacy Warrants for the six months ended December 31, 2025: | | | | | | | | | | Shares | | Price (1) | | Term (2) | Outstanding, beginning of period | | 850,442 | | $ | 19.90 | | 2.3 | Expirations | | (660) | | | 67.55 | | | Outstanding, end of period | | 849,782 | | | 19.86 | | 1.8 |
| (1) | Represents the weighted average exercise price. |
| (2) | Represents the weighted average remaining contractual term for the number of years until the warrants expire. |
|